Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease.

Hu Y, Hosseini A, Kauwe JS, Gross J, Cairns NJ, Goate AM, Fagan AM, Townsend RR, Holtzman DM.

Proteomics Clin Appl. 2007 Nov;1(11):1373-84. doi: 10.1002/prca.200600999. Epub 2007 Oct 16.

PMID:
21136637
2.

In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases.

Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA.

J Neuroinflammation. 2010 Jun 11;7:34. doi: 10.1186/1742-2094-7-34.

3.

Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.

Comabella M, Fernández M, Martin R, Rivera-Vallvé S, Borrás E, Chiva C, Julià E, Rovira A, Cantó E, Alvarez-Cermeño JC, Villar LM, Tintoré M, Montalban X.

Brain. 2010 Apr;133(Pt 4):1082-93. doi: 10.1093/brain/awq035. Epub 2010 Mar 17.

PMID:
20237129
4.

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA.

Ann Neurol. 2010 Jan;67(1):122-31. doi: 10.1002/ana.21843.

5.

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ.

Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6.

6.

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.

Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM.

EMBO Mol Med. 2009 Nov;1(8-9):371-80. doi: 10.1002/emmm.200900048.

7.

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease.

Perrin RJ, Fagan AM, Holtzman DM.

Nature. 2009 Oct 15;461(7266):916-22. doi: 10.1038/nature08538. Review.

8.

Plasma YKL-40: a potential new cancer biomarker?

Johansen JS, Schultz NA, Jensen BV.

Future Oncol. 2009 Sep;5(7):1065-82. doi: 10.2217/fon.09.66. Review.

PMID:
19792974
9.

Neurons in the white matter of the adult human neocortex.

Suárez-Solá ML, González-Delgado FJ, Pueyo-Morlans M, Medina-Bolívar OC, Hernández-Acosta NC, González-Gómez M, Meyer G.

Front Neuroanat. 2009 Jun 9;3:7. doi: 10.3389/neuro.05.007.2009. eCollection 2009.

10.

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM.

Arch Neurol. 2009 May;66(5):638-45. doi: 10.1001/archneurol.2009.55.

11.

Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis.

Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homer RJ, Kozhich AA, Humbles A, Kearley J, Coyle A, Chupp G, Reed J, Flavell RA, Elias JA.

J Exp Med. 2009 May 11;206(5):1149-66. doi: 10.1084/jem.20081271. Epub 2009 May 4.

12.

Biomarkers of Alzheimer's disease.

Craig-Schapiro R, Fagan AM, Holtzman DM.

Neurobiol Dis. 2009 Aug;35(2):128-40. doi: 10.1016/j.nbd.2008.10.003. Epub 2008 Oct 28. Review.

13.

YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages.

Létuvé S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret MC, Kiener PA, Aubier M, Coyle AJ, Pretolani M.

J Immunol. 2008 Oct 1;181(7):5167-73.

14.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
15.

YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor.

Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GC, Darko SW, Medina-Flores R, Murphey-Corb M, Rajakumar PA, Nyaundi J, Mellors JW, Bowser R, Wiley CA.

Am J Pathol. 2008 Jul;173(1):130-43. doi: 10.2353/ajpath.2008.080045. Epub 2008 Jun 13.

16.

Elevated cerebrospinal fluid and serum YKL-40 levels are not associated with symptomatic vasospasm in patients with aneurysmal subarachnoid haemorrhage.

Kacira T, Hanimoglu H, Kucur M, Sanus GZ, Kafadar AM, Tanriverdi T, Kaynar MY.

J Clin Neurosci. 2008 Sep;15(9):1011-6. doi: 10.1016/j.jocn.2006.11.014. Epub 2008 Feb 15.

PMID:
18280741
17.

Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A.

J Alzheimers Dis. 2007 Nov;12(3):255-60.

PMID:
18057559
18.

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.

Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ.

Neurology. 2007 Aug 14;69(7):631-9.

PMID:
17698783
19.

Inflammatory processes in Alzheimer's disease.

Heneka MT, O'Banion MK.

J Neuroimmunol. 2007 Mar;184(1-2):69-91. Epub 2007 Jan 12. Review.

PMID:
17222916
20.

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.

Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.

PMID:
17210801

Supplemental Content

Support Center